CTLA4 and hepatocellular carcinoma: Treatment with anti-programmed death-ligan 1 (PDL-1) plus anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) (Durvalimab plus Tremelimumab) has shown superiority over Sorafenib in improving OS in patients with unresectable HCC [7].